Emerging Role of Caveolin-1 in GLP-1 Action.
G proteins
GLP-1 receptor
caveolin-1
glucagon-like peptide-1
β-arrestin-1
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
02
2021
accepted:
22
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
24
12
2021
Statut:
epublish
Résumé
Glucagon-like peptide-1 (GLP-1) is a gut hormone mainly produced in the intestinal epithelial endocrine L cells, involved in maintaining glucose homeostasis. The use of GLP-1 analogous and dipeptidyl peptidase-IV (DPP-IV) inhibitors is well-established in Type 2 Diabetes. The efficacy of these therapies is related to the activation of GLP-1 receptor (GLP-1R), which is widely expressed in several tissues. Therefore, GLP-1 is of great clinical interest not only for its actions at the level of the beta cells, but also for the extra-pancreatic effects. Activation of GLP-1R results in intracellular signaling that is regulated by availability of downstream molecules and receptor internalization. It has been shown that GLP-1R co-localizes with caveolin-1, the main component of caveolae, small invagination of the plasma membrane, which are involved in controlling receptor activity by assembling signaling complexes and regulating receptor trafficking. The aim of this review is to outline the important role of caveolin-1 in mediating biological effects of GLP-1 and its analogous.
Identifiants
pubmed: 33935978
doi: 10.3389/fendo.2021.668012
pmc: PMC8079975
doi:
Substances chimiques
Caveolin 1
0
Dipeptidyl-Peptidase IV Inhibitors
0
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Glucagon-Like Peptide 1
89750-14-1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
668012Informations de copyright
Copyright © 2021 Puddu and Maggi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Ther. 2011 May;33(5):511-27
pubmed: 21665040
Diabetes Metab. 2013 May;39(3):195-201
pubmed: 23643349
J Mol Biol. 2020 Mar 6;432(5):1347-1366
pubmed: 31446075
Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E161-70
pubmed: 23592482
Proc Natl Acad Sci U S A. 2008 May 6;105(18):6614-9
pubmed: 18445652
J Biol Chem. 1997 Mar 7;272(10):6525-33
pubmed: 9045678
Diabetes Metab J. 2016 Apr;40(2):99-114
pubmed: 27126881
J Cell Sci. 2008 May 1;121(Pt 9):1363-72
pubmed: 18397999
Annu Rev Biochem. 1998;67:199-225
pubmed: 9759488
Recept Channels. 2002;8(3-4):179-88
pubmed: 12529935
J Biol Chem. 1999 Mar 26;274(13):8858-64
pubmed: 10085129
Mol Pharmacol. 2009 Nov;76(5):1082-93
pubmed: 19696145
Biochem Biophys Res Commun. 2018 Jan 1;495(1):223-229
pubmed: 29113797
Circ Res. 2004 Nov 12;95(10):1012-8
pubmed: 15499025
Mol Endocrinol. 2006 Dec;20(12):3400-11
pubmed: 16931572
Endocrinology. 1995 Aug;136(8):3585-96
pubmed: 7628397
Mol Cell Endocrinol. 2014 Feb 15;382(2):938-49
pubmed: 24275181
PLoS One. 2010 Nov 30;5(11):e14157
pubmed: 21152401
Trends Cardiovasc Med. 2005 Apr;15(3):92-6
pubmed: 16039968
Biochem Biophys Res Commun. 2008 Oct 17;375(2):235-7
pubmed: 18703018
Diabetes Obes Metab. 2017 Sep;19(9):1205-1213
pubmed: 28295962
Mediators Inflamm. 2013;2013:750540
pubmed: 23737653
Biochem Biophys Res Commun. 2017 Jan 29;483(1):75-81
pubmed: 28062183
Diabetes Care. 2009 May;32(5):762-8
pubmed: 19196887
Cell. 2008 Jan 11;132(1):113-24
pubmed: 18191225
J Biol Chem. 2007 Mar 30;282(13):10117-10131
pubmed: 17287217
Genome Biol. 2004;5(3):214
pubmed: 15003112
Lancet. 2006 Nov 11;368(9548):1696-705
pubmed: 17098089
Mol Pharmacol. 2005 May;67(5):1493-504
pubmed: 15703379
Am J Pathol. 2002 Oct;161(4):1357-69
pubmed: 12368209
Biochem Pharmacol. 2015 Jan 1;93(1):72-84
pubmed: 25449603
Curr Opin Rheumatol. 2008 Nov;20(6):713-9
pubmed: 18949888
Mol Biol Cell. 2001 Mar;12(3):685-98
pubmed: 11251080
Annu Rev Pharmacol Toxicol. 2008;48:359-91
pubmed: 17914930
J Endocrinol Invest. 2013 Mar;36(3):204-8
pubmed: 23404184
Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9
pubmed: 11413487
Mol Endocrinol. 1999 Dec;13(12):2013-24
pubmed: 10598578
Mol Metab. 2019 Dec;30:72-130
pubmed: 31767182
J Biol Chem. 2005 Sep 2;280(35):31036-44
pubmed: 15961389
Gastroenterology. 2007 May;132(6):2131-57
pubmed: 17498508
J Cell Sci. 2015 Apr 1;128(7):1269-78
pubmed: 25829513
J Biol Chem. 2000 Dec 29;275(52):41447-57
pubmed: 11006286
J Biol Chem. 2004 Aug 13;279(33):34614-23
pubmed: 15190056
Cell Signal. 2011 Mar;23(3):522-8
pubmed: 20849951
Mediators Inflamm. 2013;2013:975032
pubmed: 24307763
Biochem Biophys Res Commun. 2004 Mar 26;316(1):240-3
pubmed: 15003536
Biochem Pharmacol. 2018 Oct;156:406-419
pubmed: 30195733
Nat Rev Neurosci. 2007 Feb;8(2):128-40
pubmed: 17195035
Nat Commun. 2018 Apr 23;9(1):1602
pubmed: 29686402
Diabetes. 2004 Jan;53(1):5-13
pubmed: 14693691
Mol Pharmacol. 2002 Feb;61(2):352-9
pubmed: 11809860
Diabetologia. 2011 Jan;54(1):10-8
pubmed: 20871975
Nat Rev Mol Cell Biol. 2013 Feb;14(2):98-112
pubmed: 23340574